Beactica expands its drug discovery collaboration with Boehringer Ingelheim

Beactica today announced that it has expanded its collaboration with Boehringer Ingelheim. For the additional project, Beactica will use its proprietary fragment-based platform to identify novel and selective hits against oncology-relevant kinases of therapeutic interest to Boehringer Ingelheim. Financial terms of the agreement were not disclosed.

"We are pleased to expand our work with Boehringer Ingelheim and look forward to further supporting them in their discovery of innovative, new medicines for the treatment of cancer”, said Beactica CEO, Dr Per Källblad. "The collaboration builds on Beactica's strategy of establishing long-term relationships with leading pharmaceutical companies and validates the potential of our drug discovery platform”.

Beactica's collaboration with Boehringer Ingelheim was established in 2008. Previous work under the collaboration includes the contribution of important insights into the interaction mechanism of Giotrif® (afatinib), a treatment that has been recently approved for lung cancer patients with EGFR mutations in Europe and the US.
For additional information please contact Dr Per Källblad, Beactica CEO, +46 18 56 08 80.

More News